ESGO 2020 - 4th State of the Art Conference of the European Society of Gynaecological Oncology (Virtual Meeting)
Dec 14 - Dec 16, 2020 | CopenhagenDenmark
LARVOL is not affiliated with 4th State of the Art Conference of the European Society of Gynaecological Oncology (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners
Showing 20 abstracts linked to Trials
[VIRTUAL] Safety and antitumor activity of dostarlimab in patients (PTS) with advanced or recurrent DNA mismatch repair deficient (DMMR) or proficient (MMRP) endometrial cancer (EC): results from the garnet study
[VIRTUAL] Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: subgroup analysis by risk in the phase III solo1 study
[VIRTUAL] Niraparib in patients with newly diagnosed advanced ovarian brcam cancer: a post hoc analysis of the prima/engot-ov26/gog-3012 trial
[VIRTUAL] Preliminary results of anlotinib and niraparib dual therapy evaluation in platinum-resistant recurrent ovarian cancer (ANNIE): a multicenter, single-arm, phase 2 trial
[VIRTUAL] Patient-reported outcomes (PROS) in patients (PTS) receiving niraparib in the prima/engot-ov26/gog-3012 trial
[VIRTUAL] Leap-005: evaluating the safety and efficacy of lenvatinib and pembrolizumab in patients previously treated for ovarian cancer, a multi-cohort phase 2 study
[VIRTUAL] Primary imiquimod treatment versus surgery for vulvar intraepithelial neoplasia – PITVIN study. Baseline Results of a Randomized Clinical Trial
[VIRTUAL] Efficacy and safety of niraparib in older patients (PTS) with advanced ovarian cancer (OC): results from the prima/ENGOT-OV26/GOG-3012 trial
[VIRTUAL] Efficacy of niraparib therapy in patients with newly diagnosed advanced ovarian cancer by brcawt status: prima/ENGOT-OV26/GOG-3012 study
[VIRTUAL] Patient-reported outcomes (PROS) in the garnet trial in patients (PTS) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (DMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
[VIRTUAL] ENGOT-EN6/GOG-3031/NSGO-RUBY: a phase 3, randomised, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC)
[VIRTUAL] Efficacy of individualised starting dose (ISD) and fixed starting dose (FSD) of niraparib per investigator assessment (IA) in newly diagnosed advanced ovarian cancer (OC) patients
[VIRTUAL] Phase 3 trial of tumor treating fields concomitant with weekly paclitaxel for platinum-resistant ovarian cancer: ENGOT-OV50/GOG-329/INNOVATE-3
[VIRTUAL] Phase 1B trial of monalizumab (NKG2A inhibitor) plus durvalumab: safety and efficacy in patients with metastatic ovarian, cervical, and microsatellite-stable endometrial cancers
[VIRTUAL] Efficacy of a multi-ingredient coriolus versicolor-based vaginal gel in HPV+ women older than 40 years: sub-analysis of paloma clinical trial